| pubmed-article:9332462 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9332462 | lifeskim:mentions | umls-concept:C0009402 | lld:lifeskim |
| pubmed-article:9332462 | lifeskim:mentions | umls-concept:C0017638 | lld:lifeskim |
| pubmed-article:9332462 | lifeskim:mentions | umls-concept:C0076080 | lld:lifeskim |
| pubmed-article:9332462 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:9332462 | lifeskim:mentions | umls-concept:C0205329 | lld:lifeskim |
| pubmed-article:9332462 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:9332462 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:9332462 | pubmed:dateCreated | 1997-11-13 | lld:pubmed |
| pubmed-article:9332462 | pubmed:abstractText | Patients with progressive or recurrent supratentorial high-grade gliomas were entered into a multicentre phase II trial to evaluate the efficacy and toxicity of temozolomide. | lld:pubmed |
| pubmed-article:9332462 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9332462 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9332462 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9332462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9332462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9332462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9332462 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9332462 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:9332462 | pubmed:author | pubmed-author:LewisPP | lld:pubmed |
| pubmed-article:9332462 | pubmed:author | pubmed-author:BleehenN MNM | lld:pubmed |
| pubmed-article:9332462 | pubmed:author | pubmed-author:NewlandsE SES | lld:pubmed |
| pubmed-article:9332462 | pubmed:author | pubmed-author:CalvertHH | lld:pubmed |
| pubmed-article:9332462 | pubmed:author | pubmed-author:BradaMM | lld:pubmed |
| pubmed-article:9332462 | pubmed:author | pubmed-author:ColquhounII | lld:pubmed |
| pubmed-article:9332462 | pubmed:author | pubmed-author:BowenII | lld:pubmed |
| pubmed-article:9332462 | pubmed:author | pubmed-author:BramptonM HMH | lld:pubmed |
| pubmed-article:9332462 | pubmed:author | pubmed-author:BegentR JRJ | lld:pubmed |
| pubmed-article:9332462 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9332462 | pubmed:volume | 40 | lld:pubmed |
| pubmed-article:9332462 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9332462 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9332462 | pubmed:pagination | 484-8 | lld:pubmed |
| pubmed-article:9332462 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9332462 | pubmed:meshHeading | pubmed-meshheading:9332462-... | lld:pubmed |
| pubmed-article:9332462 | pubmed:meshHeading | pubmed-meshheading:9332462-... | lld:pubmed |
| pubmed-article:9332462 | pubmed:meshHeading | pubmed-meshheading:9332462-... | lld:pubmed |
| pubmed-article:9332462 | pubmed:meshHeading | pubmed-meshheading:9332462-... | lld:pubmed |
| pubmed-article:9332462 | pubmed:meshHeading | pubmed-meshheading:9332462-... | lld:pubmed |
| pubmed-article:9332462 | pubmed:meshHeading | pubmed-meshheading:9332462-... | lld:pubmed |
| pubmed-article:9332462 | pubmed:meshHeading | pubmed-meshheading:9332462-... | lld:pubmed |
| pubmed-article:9332462 | pubmed:meshHeading | pubmed-meshheading:9332462-... | lld:pubmed |
| pubmed-article:9332462 | pubmed:meshHeading | pubmed-meshheading:9332462-... | lld:pubmed |
| pubmed-article:9332462 | pubmed:meshHeading | pubmed-meshheading:9332462-... | lld:pubmed |
| pubmed-article:9332462 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9332462 | pubmed:articleTitle | Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. | lld:pubmed |
| pubmed-article:9332462 | pubmed:affiliation | Department of Medical Oncology, Charing Cross Hospital, London, UK. | lld:pubmed |
| pubmed-article:9332462 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9332462 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9332462 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:9332462 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9332462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9332462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9332462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9332462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9332462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9332462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9332462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9332462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9332462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9332462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9332462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9332462 | lld:pubmed |
